Sunway Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 30-06-2024
- Paid Up Capital ₹ 3.88 Cr
as on 30-06-2024
- Company Age 15 Year, 2 Days
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 3.22 Cr
as on 30-06-2024
- Revenue -23.25%
(FY 2019)
- Profit -787.77%
(FY 2019)
- Ebitda 74.05%
(FY 2019)
- Net Worth -8.75%
(FY 2019)
- Total Assets 6.83%
(FY 2019)
About Sunway Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 3.88 Cr.
The company has closed loans amounting to ₹3.22 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Bali Reddy, Ravender Gatla, and Maheshkumar Venna serve as directors at the Company.
- CIN/LLPIN
U24297TG2009PTC066411
- Company No.
066411
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Dec 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Medak, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Sunway Life Sciences Private Limited offer?
Sunway Life Sciences Private Limited offers a wide range of products and services, including Pain Reliever Gel, Combiflam Gel, Pain Relief Drugs & Pharmaceuticals, Pain Relief Spray, Paracetamol Tablets, Combiflam Tablet, Combiflam Pain Relief Spray.
Who are the key members and board of directors at Sunway Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bali Reddy  | Director | 10-Mar-2014 | Current |
| Ravender Gatla | Director | 12-Mar-2014 | Current |
| Maheshkumar Venna | Director | 12-Mar-2014 | Current |
Financial Performance of Sunway Life Sciences.
Sunway Life Sciences Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 23.25% decrease. The company also saw a substantial fall in profitability, with a 787.77% decrease in profit. The company's net worth dipped by a decrease of 8.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sunway Life Sciences?
In 2018, Sunway Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Nov 2014 | ₹3.22 Cr | Satisfied |
How Many Employees Work at Sunway Life Sciences?
Sunway Life Sciences has a workforce of 15 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sunway Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sunway Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
